PROTAC target BCL6（Arvinas）

N/A

Report date: 2023/03/02 17:20:30
NME

Base Information

Drug NamePROTAC target BCL6（Arvinas）
Drug Alias NameBCL6 targeting PROTACs drug（Arvinas）
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionB-cell lymphoma 6 protein degraders
TargetsB-cell lymphoma 6 protein
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesArvinas Inc
China Registration ClassN/A

Develop Information

Active CompaniesArvinas Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A